Journal of Clinical Oncology
Articles in this Issue
Multivariate survival analysis and prevalence disparities in spindle cell carcinoma: A SEERStat-based retrospective study.
e21569 Background: Spindle cell carcinoma (SpCC) is a rare and aggressive variant of squamous cell carcinoma. It is often...
Machine learning–based identification of patients at risk for early infectious complications after CAR-T in multiple myeloma.
e19518 Background: Infections occur in 50–70% of Multiple Myeloma(MM) patients after CAR T therapy, with the highest risk...
The role of coaching in enhancing clinical oncology academic performance.
9040 Background: Oncology faculty in academic medicine navigate a multitude of demands spanning clinical care, research, t...
Randomized phase I/II trial adjuvant CD40.HVAC, an immunotherapy engaging dendritic cells (DC), in patients with HPV16+ oropharyngeal carcinoma (OPC).
6018 Background: Up to 70% of OPCs are HPV-mediated predominantly by HPV16. E6/E7 oncoproteins, constitutively expressed i...
Associations between early on-treatment weight change and overall survival across targeted therapies in chronic lymphocytic leukemia.
e19001 Background: Targeted therapies for chronic lymphocytic leukemia (CLL) include BTK inhibitors (ibrutinib, acalabruti...
Quality of life in cancer patients treated with anchored interleukin-12 (IL-12) immunotherapy: Results from a first-in-human phase 1 trial of tolododekin alfa (ANK-101).
2593 Background: Anchored immunotherapy is a novel method for retaining high concentrations of anti-tumor drugs in establi...
Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.
7508 Background: Data on response to BCMA-targeted therapies among BCMA-exposed pts with RRMM are limited. Outcomes after...
Combining zanidatamab, FOLFOX, and pembrolizumab as first-line therapy for HER2/PD-L1–positive gastroesophageal adenocarcinoma: The phase ll IKF-090/AIO ZANGEA trial with translational analysis.
TPS4244 Background: Gastroesophageal adenocarcinoma (GEA) presents a substantial global health challenge as the number of...
The enzymatic component of the nitric oxide system in mitochondria of melanoma and skin: What changes occur?
e21537 Background: Malignant melanoma has a multifactorial etiology and a heterogeneous course. Modern concepts about the...
Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).
6535 Background: For adults with ND Ph- B-ALL, frontline regimens now often include the CD19/CD3 bispecific blinatumomab (...
Immunotherapy for uncommon <i>EGFR</i> mutations in lung adenocarcinoma.
e20613 Background: While common EGFR mutations (ex19del/L858R) are associated with...
Performance of the NutriPal nutritional screening algorithm in advanced cancer palliative care: A multicenter study.
12062 Background: Malnutrition is highly prevalent in advanced cancer and is closely associated with functional decline, s...
Association of clonal hematopoiesis driven by mosaic chromosomal alterations with epigenetic age in the PLCO trial.
10556 Background: Mosaic chromosomal alterations (mCAs) are age-associated clonal events detectable in peripheral blood an...
Multiple myeloma incidence, prevalence, and mortality burden in the United States: Retrospective epidemiological trends and burden (1990–2023) with machine learning-based projections to 2050.
e19546 Background: Multiple myeloma, a plasma cell malignancy, imposes a substantial disease burden in the United States,...
Real-world outcomes with atezolizumab versus durvalumab plus chemotherapy for extensive-stage small cell lung cancer: A TriNetX propensity-matched analysis.
11145 Background: First-line treatment for extensive-stage small cell lung cancer (ES-SCLC) consists of platinum-etoposide...
A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.
TPS7101 Background: Patients with high-risk CLL/SLL not achieving a complete response (CR) after ≥ 12 months of BTK inhibi...
Impact of the Breast Cancer Index on extended endocrine therapy recommendations in patients from the BCI Registry study.
527 Background: The Breast Cancer Index (BCI) test is an established genomic assay that provides individualized risks of o...
Correlation of an IGF1R RNA activation signature with allostatic load and time to castration resistance in primary prostate cancer patients.
e17026 Background: Insulin-like Growth Factor 1 Receptor (IGF1R) functions as a central mediator of nutrient sensing and e...
Dexamethasone reduction or omission with NEPA and olanzapine for HEC: A phase III trial.
12000 Background: Prolonged dexamethasone (DEX) in antiemetic regimens for highly emetogenic chemotherapy (HEC) ma...
Early-onset chronic and metabolic morbidity among survivors of childhood acute lymphoblastic leukemia: Evidence from Middle Eastern real-world data.
10049 Background: Survivors of childhood acute lymphoblastic leukemia (ALL) are at increased risk of long-term morbidity;...
Digital information–seeking behavior in patients with cancer through storytelling.
9044 Background: Peer support for cancer patients through narrative interventions can have benefits for quality of life, e...
Disparities in utilization of genomic risk assays in early-stage hormone-positive breast cancer: A retrospective analysis using National Cancer Database (NCDB).
537 Background: Prognostic genomic assays (GA) have become crucial in the management of early-stage hormone receptor posit...
Impact of radiologically identified embryological origin on recurrence patterns and survival in resectable pancreatic head adenocarcinoma.
4228 Background: The pancreatic head develops embryologically from the fusion of the dorsal pancreatic (Dp) and ventral pa...
Stage-specific comparative effectiveness of locoregional therapies in early-stage hepatocellular carcinoma: A global real-world analysis.
e16277 Background: Locoregional therapies are central to the management of early-stage hepatocellular carcinoma (HCC) in p...
Acute care events after outpatient systemic therapy among patients at elevated risk for acute care utilization.
e23246 Background: A subset of acute care events (ACE) within 30 days of outpatientsystemic therapy is potentially prevent...